50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.37 (-2.88%)
GOOGL   98.17 (-0.58%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.37 (-2.88%)
GOOGL   98.17 (-0.58%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.37 (-2.88%)
GOOGL   98.17 (-0.58%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
QQQ   274.37 (-0.41%)
AAPL   150.77 (+0.23%)
MSFT   237.45 (-0.20%)
META   136.37 (-2.88%)
GOOGL   98.17 (-0.58%)
AMZN   115.15 (+1.20%)
TSLA   276.01 (+0.25%)
NVDA   122.28 (-2.30%)
NIO   17.62 (-0.11%)
BABA   78.91 (+0.14%)
AMD   66.30 (-2.44%)
T   15.67 (-2.12%)
MU   48.88 (-2.44%)
CGC   2.74 (-3.52%)
F   11.99 (-2.60%)
GE   64.35 (-0.31%)
DIS   98.12 (-1.39%)
AMC   6.83 (-14.52%)
PYPL   84.26 (-3.12%)
PFE   43.83 (-0.57%)
NFLX   224.07 (-1.03%)
NASDAQ:OTIC

Otonomy - OTIC Stock Forecast, Price & News

$0.28
0.00 (0.00%)
(As of 09/26/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.27
$0.34
50-Day Range
$0.25
$2.22
52-Week Range
$0.24
$2.59
Volume
459,748 shs
Average Volume
696,438 shs
Market Capitalization
$15.87 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.50

Otonomy MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
1,515.8% Upside
$4.50 Price Target
Short Interest
Healthy
1.32% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.25mentions of Otonomy in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.73) to ($0.58) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

550th out of 1,069 stocks

Pharmaceutical Preparations Industry

253rd out of 533 stocks

OTIC stock logo

About Otonomy (NASDAQ:OTIC) Stock

Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Receive OTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Otonomy and its competitors with MarketBeat's FREE daily newsletter.

OTIC Stock News Headlines

Otonomy Q2 2022 Earnings Preview - Seeking Alpha
See More Headlines
Receive OTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Otonomy and its competitors with MarketBeat's FREE daily newsletter.

OTIC Company Calendar

Last Earnings
7/25/2022
Today
9/26/2022
Next Earnings (Estimated)
11/09/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OTIC
Employees
51
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.50
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$3.00
Forecasted Upside/Downside
+1,515.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-51,180,000.00
Pretax Margin
-150,065.70%

Debt

Sales & Book Value

Annual Sales
$130,000.00
Book Value
$0.97 per share

Miscellaneous

Free Float
51,804,000
Market Cap
$15.87 million
Optionable
Optionable
Beta
1.49

Key Executives

  • Dr. David Allen Weber (Age 62)
    Pres, CEO & Director
    Comp: $907.68k
  • Mr. Paul E. Cayer (Age 60)
    Chief Financial & Bus. Officer
    Comp: $598.22k
  • Mr. Robert Michael Savel II (Age 54)
    Chief Technical Officer
    Comp: $534.58k
  • Dr. Allen F. Ryan Ph.D.
    Co-Founder and Member of the Advisory Panel
  • Dr. Rick Adam Friedman M.D.
    Ph.D., Co-Founder and Member of the Advisory Panel
  • Dr. Alan Charles Foster Ph.D. (Age 66)
    Chief Scientific Officer
  • Ms. Breianna Bowen
    VP of HR
  • Ms. Barbara M. Finn
    Sr. VP of Regulatory Affairs & Quality Assurance
  • Dr. Fabrice Piu Ph.D.
    Sr. VP of Preclinical Devel.
  • Mr. David Skarinsky
    Sr. VP of Clinical













OTIC Stock - Frequently Asked Questions

Should I buy or sell Otonomy stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OTIC shares.
View OTIC analyst ratings
or view top-rated stocks.

What is Otonomy's stock price forecast for 2022?

3 equities research analysts have issued 12-month price targets for Otonomy's shares. Their OTIC share price forecasts range from $3.00 to $6.00. On average, they predict the company's share price to reach $4.50 in the next year. This suggests a possible upside of 1,400.0% from the stock's current price.
View analysts price targets for OTIC
or view top-rated stocks among Wall Street analysts.

How have OTIC shares performed in 2022?

Otonomy's stock was trading at $2.08 at the beginning of the year. Since then, OTIC shares have decreased by 85.6% and is now trading at $0.30.
View the best growth stocks for 2022 here
.

When is Otonomy's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our OTIC earnings forecast
.

How were Otonomy's earnings last quarter?

Otonomy, Inc. (NASDAQ:OTIC) announced its quarterly earnings data on Monday, July, 25th. The biopharmaceutical company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.20) by $0.01. During the same quarter in the prior year, the company posted ($0.19) earnings per share.

What other stocks do shareholders of Otonomy own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird (), Wellington Shields () and Macquarie ().

What is Otonomy's stock symbol?

Otonomy trades on the NASDAQ under the ticker symbol "OTIC."

Who are Otonomy's major shareholders?

Otonomy's stock is owned by a variety of retail and institutional investors. Top institutional investors include DAFNA Capital Management LLC (2.58%), Silverarc Capital Management LLC (1.83%), Group One Trading L.P. (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include David Allen Weber, Jay Lichter and Robert Michael Savel II.
View institutional ownership trends
.

How do I buy shares of Otonomy?

Shares of OTIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Otonomy's stock price today?

One share of OTIC stock can currently be purchased for approximately $0.30.

How much money does Otonomy make?

Otonomy (NASDAQ:OTIC) has a market capitalization of $17.10 million and generates $130,000.00 in revenue each year. The biopharmaceutical company earns $-51,180,000.00 in net income (profit) each year or ($0.78) on an earnings per share basis.

How can I contact Otonomy?

Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The official website for the company is www.otonomy.com. The biopharmaceutical company can be reached via phone at (619) 323-2200, via email at ir@otonomy.com, or via fax at 619-291-9190.

This page (NASDAQ:OTIC) was last updated on 9/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.